OR10-006 - Canakinumab in patients with TRAPS
نویسندگان
چکیده
Introduction TNF-receptor associated periodic syndrome (TRAPS) is a rare, dominantly inherited periodic fever syndrome due to mutations of the TNFRSF1A gene. The IL-1 receptor antagonist anakinra has been reported to be an efficacious daily treatment. Canakinumab (CAN) is a fully human monoclonal selective anti-IL-1b antibody with a T1/2 of ~4 wks. Interim clinical and PK data of CAN treatment in patients with active TRAPS are presented.
منابع مشابه
Canakinumab reverses overexpression of inflammatory response genes in tumour necrosis factor receptor-associated periodic syndrome
OBJECTIVE To explore whether gene expression profiling can identify a molecular mechanism for the clinical benefit of canakinumab treatment in patents with tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS Blood samples were collected from 20 patients with active TRAPS who received canakinumab 150 mg every 4 weeks for 4 months in an open-label proof-of-concept phas...
متن کاملCanakinumab treatment for patients with active recurrent or chronic TNF receptor-associated periodic syndrome (TRAPS): an open-label, phase II study
OBJECTIVE To evaluate the efficacy of canakinumab, a high-affinity human monoclonal anti-interleukin-1β antibody, in inducing complete or almost complete responses in patients with active tumour necrosis factor receptor-associated periodic syndrome (TRAPS). METHODS Twenty patients (aged 7-78 years) with active recurrent or chronic TRAPS were treated with canakinumab 150 mg every 4 weeks for 4...
متن کاملOR10-002 - A novel TNFR1 transcript of TRAPS gene
Methods Expression of TNFRSF1A transcripts was performed by RT-PCR in a range of human cells and tissues. Exon 2 splicing and transcriptional activity were analysed in HEK293T and SW480 cells by in vitro alternative splicing and luciferase assays, respectively. We constructed haplotypes containing rs4149570, rs767455 and rs1800692 in controls (n=70), TRAPS (n=111) and TRAPS-like patients (n=450...
متن کاملCanakinumab treatment in patients with active recurrent or chronic TNF-receptor associated syndrome (TRAPS): Efficacy and safety results from a proof of concept study
Introduction Tumor necrosis factor receptor-1 associated periodic syndrome (TRAPS) is a periodic fever syndrome, characterized by recurrent fever attacks associated with rashes, musculoskeletal and abdominal pain, and periorbital edema. In few patients TNF inhibitors have been shown to be effective, however, their efficacy tends to decrease over time [1-4]. Anti-IL-1 treatments have also been u...
متن کاملPW03-006 - IL-1-B inhibition in Schnitzler’s syndrome
Methods In an open-label, single-treatment arm trial, eight patients with Schnitzler’s syndrome received monthly injections with 150 mg canakinumab subcutaneously for 6 months, followed by a 3-month observation period. Primary outcome was complete or clinical remission at day 14. Secondary outcome measures included inflammatory markers, quality of life, time to relapse, safety and tolerability.
متن کامل